<DOC>
	<DOCNO>NCT01027169</DOCNO>
	<brief_summary>The primary purpose study investigate pharmacokinetics ( behavior compound body ) safinamide patient different degree hepatic ( liver ) impairment comparison match subject normal hepatic function .</brief_summary>
	<brief_title>A Study Assess Effect Hepatic Impairment Safinamide Pharmacokinetics</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>Hepatically impaired subject Subjects liver cirrhosis different degree impair hepatic function : mild moderate impair hepatic function ( Grade A , B accord ChildPugh classification ) Healthy subject Subject good ageappropriate physical mental health establish medical history , physical examination , ECG vital sign recording , result biochemistry , haematology , coagulation urinalysis test within 3 week prior dose All subject give write informed consent studyrelated activity carry Any clinically relevant disease condition , Investigator 's opinion would exclude subject study Diseases surgeries gastrointestinal tract , could influence gastrointestinal absorption and/or motility Hepatically impaired subject Subjects primary biliary liver cirrhosis , hepatic encephalopathy grade III IV , sepsis spontaneous bacterial peritonitis , gastrointestinal bleeding within one month study , esophagus varix &gt; grade II , acute hepatic failure aetiology , portosystemic shunt , renal impairment ( creatinine clearance &lt; 50 mL/min calculate use Cockroft Gault formula ) Healthy subject Use medication , include multivitamin preparation , receive within 21 day prior drug administration , within six time elimination halflife , whichever long , except combine oral contraceptive occasional use paracetamol ibuprofen within 14 day study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Hepatic impairment</keyword>
	<keyword>Liver disease</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>To Investigate Pharmacokinetics Safinamide Subjects With Mild Moderate Hepatic Impairment Compared Healthy Subjects With Normal Hepatic Function</keyword>
</DOC>